Novo Nordisk Seeks Injunction to Block Eli Lilly Weight-Loss Drug Ads

Novo Nordisk has filed a motion in a U.S. court seeking a preliminary injunction to prevent Eli Lilly & Co. from continuing its advertising campaigns for weight-loss drugs Zepbound and Mounjaro. Novo alleges that the ads rely on outdated clinical data and omit the higher-dose versions of Wegovy and Ozempic, misleading consumers and healthcare providers.

Details of the Action

According to the filing, Lilly's ads compare the efficacy of Zepbound and Mounjaro with Wegovy and Ozempic using data from older clinical trials that do not reflect the currently approved higher doses of Wegovy and Ozempic. Novo is requesting an immediate halt to these ads until the case is resolved.

Company Position

Eli Lilly denied the allegations, stating that its ads are accurate and based on FDA-approved data. The company said it will vigorously defend against the lawsuit.

Precedents and Context

This is not the first legal dispute between the two companies over obesity drug advertising. Last year, Lilly filed a similar lawsuit against Novo regarding Ozempic ads, which was settled out of court. The obesity drug market is fiercely competitive, estimated to be worth tens of billions of dollars.

Potential Financial Impact

If Novo succeeds in obtaining the injunction, Lilly may be forced to modify or halt its ad campaigns, potentially impacting sales of Zepbound and Mounjaro. The legal battle is expected to continue for several months.